BSE Live
Dec 24, 16:01Prev. Close
1216.80
Open Price
1216.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 24, 15:55Prev. Close
1218.00
Open Price
1220.90
Bid Price (Qty.)
1211.40 (15)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Aurobindo Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 2,377.70 | 1,964.62 | 2,342.94 | 2,178.57 | 2,147.84 | |
| Net CashFlow From Operating Activities | 2,161.73 | 529.89 | 922.40 | 2,457.20 | 1,185.18 | |
| Net Cash Used In Investing Activities | -921.57 | -1,297.36 | -990.60 | -1,542.05 | -1,390.11 | |
| Net Cash Used From Financing Activities | -1,252.39 | 599.40 | 439.69 | -1,328.99 | 514.97 | |
| Foreign Exchange Gains / Losses | 2.97 | -3.18 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -9.26 | -171.25 | 371.49 | -413.84 | 310.04 | |
| Cash And Cash Equivalents Begin of Year | 68.70 | 239.95 | -131.54 | 283.90 | -26.14 | |
| Cash And Cash Equivalents End Of Year | 59.44 | 68.70 | 239.95 | -129.94 | 283.90 |
19.12.2025
15.12.2025
04.12.2025
23.11.2025
Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL